Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is FLT180a, a gene therapy product candidate that is in Phase 1/2 dose-finding clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in dose-escalating Phase 1/2 clinical trials for the treatment of Fabry disease; FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease; and FLT210, a liver-directed gene therapy product candidate for the treatment of hemophilia A. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
IPO Year: 2020
Exchange: NASDAQ
Website: freeline.life
Date | Price Target | Rating | Analyst |
---|---|---|---|
2/1/2022 | Overweight → Equal-Weight | Morgan Stanley | |
1/7/2022 | Neutral → Buy | Redburn | |
11/29/2021 | $10.00 | Buy | BTIG |
8/18/2021 | $30.00 → $20.00 | Buy | HC Wainwright & Co. |
8/17/2021 | $27.00 → $8.00 | Overweight → Neutral | JP Morgan |
8/17/2021 | Overweight → Neutral | JP Morgan |
Late-breaking oral presentation on results from Phase 1/2 study of FLT201 in Gaucher disease Poster presentation to highlight Freeline's GBA1 Parkinson's disease research program LONDON, April 24, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics today announced the acceptance of multiple abstracts, including one for a late-breaking oral presentation on new clinical data from its Gaucher disease program, at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting taking place May 7-11, 2024 in Baltimore, Maryland. "Gaucher disease is a severe and progressive disorder that leads to a wide range of symptoms, including enlarged organs, bone pain and fractures, low bl
LONDON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that, in connection with Syncona's acquisition of Freeline by way of a scheme of arrangement (the "Scheme"), the Scheme has been sanctioned by the Court and the court order (together with a copy of the scheme circular published by Freeline on January 18, 2024 (the "Scheme Circular") has been delivered to the Registrar of Companies. Accordingly, the Scheme has become Effective in accordance with its terms and the entire issued share capital of Freeline is now owned or controlled by Syncona Portfolio Limited. Capitalized terms in this an
LONDON, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) ("Freeline") and Syncona Ltd ("Syncona") today announced that Freeline's shareholders have approved the proposal for Bidco 1354 Limited ("Bidco"), a wholly owned subsidiary of Syncona Portfolio Limited ("Syncona Portfolio"), to acquire all shares of Freeline not currently owned by Syncona Portfolio for $6.50 per American Depositary Share ("ADS") in cash (the "Acquisition"). As previously announced, Freeline and Bidco entered into an implementation agreement on November 22, 2023 to implement the Acquisition by means of a scheme of arrangement pursuant to Part 26 of the UK Companies Act 2006 (the "Sche
Freeline shareholders to receive $6.50 per American Depositary Share, a 51% premium over closing price prior to announcement of Syncona's initial proposal on October 18, in an all-cash transaction Based on extensive evaluation of available strategic and financing options, Freeline's independent directors unanimously recommend transaction as best value for shareholders Syncona to provide $15 million in convertible debt financing to cover Freeline's near-term capital needs and support ongoing advancement of its programs LONDON, Nov. 22, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that it has entered into a definitive agreement with a newly es
Substantial reduction in lyso-Gb1 substrate levels, an established biomarker of clinical response, observed in first patient treated with FLT201 Increases of several hundredfold over baseline in plasma GCase activity and normalization of cellular GCase levels continue to be observed in first two patients treated with FLT201 FLT201 continues to be well-tolerated, with no serious adverse events Third patient dosed this month in ongoing Phase 1/2 GALILEO-1 trial LONDON, Oct. 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus
LONDON, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that it will present new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus (AAV) gene therapy candidate, in patients with Gaucher disease Type 1 at the European Society of Gene & Cell Therapy (ESGCT) 30th Annual Congress being held October 24-27, 2023 in Brussels, Belgium. The oral presentation will include data on safety, tolerability, GCase enzyme activity, substrate, and hemoglobin and platelet levels from the first two patients treated with FLT201. Details of the oral presentation are below: Presentation Title: Results fr
Robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma FLT201 has been well tolerated, with no serious adverse events Company to host conference call today at 8 a.m. ET LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease. Gaucher disease is a debilitatin
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase variant with research program for GBA1-linked Parkinson's disease Management to host conference call at 8:00 a.m. ET today LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported financial results for the second quarter of 2023 and provided a business update. "FLT201 is a potential first- and best-in-class gene therapy for Gaucher disease Type 1, the most common type of the disease," said Michael Parini, Chief Exec
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update. Participants may access this event via the teleconferencing numbers below and asking to join the Freeline call or through the webcast link here. Domestic: 1-866-524-3160International: 1-412-317-6760 While not required, it is recommended that participants join the call 10 minutes prior to the scheduled start. A live webcast of the call will also be available on the Investors section of Freeline's website at ww
LONDON, July 31, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that the company will be participating in two upcoming investor conferences in August. Details are as follows: BTIG Virtual Biotechnology Conference Freeline Chief Executive Officer Michael Parini will participate in a fireside chat at 10 a.m. ET on Monday, August 7. Management will also participate in one-on-one meetings as part of the virtual conference. Wedbush Healthcare Conference Management will participate in one-on-one investor meetings at the conference, which is taking place from August 8-9 at the Lotte Palace Hotel in New York City. A live webcast of the BTIG fireside
Robust increases of up to 700-fold over baseline in plasma GCase enzyme activity in first two patients treated with FLT201 Normalization of leukocyte GCase in both patients demonstrates cellular uptake from plasma FLT201 has been well tolerated, with no serious adverse events Company to host conference call today at 8 a.m. ET LONDON, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported positive initial safety, tolerability and enzyme activity data from the ongoing Phase 1/2 GALILEO-1 trial evaluating FLT201, its adeno-associated virus (AAV) gene therapy candidate, in Gaucher disease. Gaucher disease is a debilitatin
Completed dosing in first cohort of Phase 1/2 GALILEO-1 trial of FLT201 in Gaucher disease; expect to report initial clinical data in third quarter of 2023 Extending impact of its novel GCase variant with research program for GBA1-linked Parkinson's disease Management to host conference call at 8:00 a.m. ET today LONDON, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today reported financial results for the second quarter of 2023 and provided a business update. "FLT201 is a potential first- and best-in-class gene therapy for Gaucher disease Type 1, the most common type of the disease," said Michael Parini, Chief Exec
LONDON, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, August 15, 2023 to report its second quarter financial results and provide a corporate update. Participants may access this event via the teleconferencing numbers below and asking to join the Freeline call or through the webcast link here. Domestic: 1-866-524-3160International: 1-412-317-6760 While not required, it is recommended that participants join the call 10 minutes prior to the scheduled start. A live webcast of the call will also be available on the Investors section of Freeline's website at ww
LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, April 4, 2023 to report its full year 2022 financial results and provide a corporate update. To access the conference call, participants may register here. While not required, it is recommended that participants join the call 10 minutes prior to the scheduled start. A live webcast of the call will also be available on the Investors section of Freeline's website at www.freeline.life. An archived replay of the webcast be available for approximately 90 days following the call. About Freeline TherapeuticsF
On track to complete dosing of the first cohort and share initial data by the end of the first half of 2022 On track to start pivotal Phase 3 trial in 2023 LONDON, March 09, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline") today announced that the first patient was dosed in its Phase 1/2 B-LIEVE dose-confirmation clinical trial of FLT180a for the treatment of hemophilia B, a debilitating genetic bleeding disorder caused by a deficiency in the clotting factor IX protein. FLT180a uses a potent and proprietary adeno-associated virus vector capsid (AAVS3) to deliver the functioning gene of a variant of human factor IX and restore normal
15-12G - Freeline Therapeutics Holdings plc (0001810031) (Filer)
EFFECT - Freeline Therapeutics Holdings plc (0001810031) (Filer)
S-8 POS - Freeline Therapeutics Holdings plc (0001810031) (Filer)
S-8 POS - Freeline Therapeutics Holdings plc (0001810031) (Filer)
S-8 POS - Freeline Therapeutics Holdings plc (0001810031) (Filer)
S-8 POS - Freeline Therapeutics Holdings plc (0001810031) (Filer)
POS AM - Freeline Therapeutics Holdings plc (0001810031) (Filer)
SC 13E3/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
25-NSE - Freeline Therapeutics Holdings plc (0001810031) (Subject)
6-K - Freeline Therapeutics Holdings plc (0001810031) (Filer)
SC 13D/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
SC 13D/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
SC 13D/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
SC 13G - Freeline Therapeutics Holdings plc (0001810031) (Subject)
SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
SC 13G/A - Freeline Therapeutics Holdings plc (0001810031) (Subject)
Morgan Stanley downgraded Freeline Therapeutics from Overweight to Equal-Weight
Redburn upgraded Freeline Therapeutics from Neutral to Buy
BTIG initiated coverage of Freeline Therapeutics with a rating of Buy and set a new price target of $10.00
HC Wainwright & Co. reiterated coverage of Freeline Therapeutics with a rating of Buy and set a new price target of $20.00 from $30.00 previously
JP Morgan downgraded Freeline Therapeutics from Overweight to Neutral and set a new price target of $8.00 from $27.00 previously
JP Morgan downgraded Freeline Therapeutics from Overweight to Neutral
HC Wainwright & Co. initiated coverage of Freeline Therapeutics with a rating of Buy and set a new price target of $30.00
Guggenheim initiated coverage of Freeline Therapeutics with a rating of Buy and set a new price target of $17.00
Morgan Stanley reiterated coverage of Freeline Therapeutics with a rating of Overweight and set a new price target of $22.00 from $28.00 previously
Mizuho initiated coverage of Freeline Therapeutics with a rating of Buy and set a new price target of $27.00
Genespire appoints Dr. Sabah Sallah as Chief Medical Officer Accomplished executive with extensive preclinical and clinical gene therapy experience joins Genespire to accelerate pipeline to the clinic Milan, Italy, 7 July 2022: Genespire, a next generation gene therapy company developing first-in-class transformative therapies with advanced lentiviral vectors, today announces the appointment of Dr. Sabah Sallah MD, PhD as Chief Medical Officer. Dr. Sallah will lead the Company's clinical strategy, development and operations as Genespire progresses its novel advanced lentiviral gene therapy platforms towards the clinic. Dr. Sallah is a board-certified hematologist who has spent more than
LONDON, April 19, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline") today announced that Paul M. Schneider has been appointed Chief Financial Officer (CFO), effective May 16, 2022, based in Boston. Mr. Schneider joins Freeline from Exo Therapeutics, Inc., where he served as Senior Vice President, Finance and Operations. A seasoned financial executive with more than 20 years of leadership experience in large and small private and public biopharmaceutical companies, Mr. Schneider brings an impressive track record of financial stewardship, including corporate strategy and execution, financial planning, analysis and reporting, and investor
LONDON, Feb. 03, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative adeno-associated virus ("AAV") vector-mediated systemic gene therapies for people with inherited systemic debilitating diseases, today announced the expansion of its executive leadership team with the appointment of Henning R. Stennicke, PhD, as Chief Scientific Officer (CSO). Dr. Stennicke has been appointed to the role of CSO effective March 1, 2022. He will be based in Stevenage, UK, and report to Michael Parini, Freeline's Chief Executive Officer, as part of the executive leadership team. As CSO, Dr.
Lowest dose cohort of MARVEL-1 trial of FLT190 for Fabry disease demonstrates durable α-Gal A expression over two years in the first patient and promising efficacy with near normal α-Gal A levels in the second patient, who remains off enzyme replacement therapy more than 16 weeks post-dosing Third patient in MARVEL-1 to be dosed at 7.5e11 vg/kg dose level in first quarter 2022 with additional safety monitoring after case of mild and transient myocarditis observed FLT201 Phase 1/2 trial for Gaucher disease Type 1 on track for trial site initiation by year-end; FLT180a Phase 1/2 dose confirmation trial for hemophilia B to be in clinic by first quarter 2022
CAMBRIDGE, England, July 5, 2021 /PRNewswire/ -- Transine Therapeutics, a biotechnology company developing a novel class of therapeutic RNAs based on its pioneering SINEUP® platform technology, today announced the appointment of Jan Thirkettle, Ph.D. as its Chief Executive Officer. He joins Transine's team at a time of rapid growth following the Company's recent successful £9.1 million extended Seed financing, which was co-led by Takeda Ventures, Inc. and the Dementia Discovery Fund. Dr Thirkettle has close to 25 years' experience of building cross-functional teams to drive delivery of innovative technologies. Jan has built platforms and played a leadership role in the commercialisation of
Appointment of Chief Technical Operations Officer James Bircher continues evolution of leadership team to execute across near- and long-term priorities Amit Nathwani, MD, PhD to return to Chief Scientific Officer role on an interim basis to replace departing Chief Scientific Officer Romuald Corbau LONDON, June 30, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced the expansion of its executive leadership team with the appointment of James "Jay" Bircher as Ch
FLT190 Phase 1/2 dose-finding study in Fabry disease on track to dose additional patients; Company to present data by year-end FLT201 Phase 1/2 dose-finding study in Gaucher disease Type 1 expected to be in the clinic by year-end FLT180a Phase 1/2 dose-confirmation study in Hemophilia B on track to initiate trial sites by year-end LONDON, May 17, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (NASDAQ:FRLN) (the "Company" or "Freeline"), a clinical-stage biotechnology company developing transformative AAV-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today reported financial results for the first quarter of 2021 and provided a
Plans to have three AAV gene therapy programs in the clinic by year-end 2021 Data from FLT180a Phase 1/2 trial for Hemophilia B demonstrated potential for durable normalization of Factor IX activity Strong 2020 year-end cash position of $230 million funds key upcoming clinical milestones LONDON, March 31, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, today reported financial results for the full year 2020 and provided an update on recent business highlights.
LONDON, March 11, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative gene therapies for patients suffering from inherited systemic debilitating diseases, announced today the appointment of Colin A. Love, PhD, to its Board of Directors with immediate effect. Dr. Love has over 30 years of experience leading biopharmaceutical company operations, including the development and launch of several biotechnology products. “We are delighted to welcome Colin Love to Freeline’s Board of Directors,” said Theresa Heggie, Chief Executive Officer of Freeline. “His appointment comes at a
Michael J. Parini joins from Vertex as President and Chief Operating Officer complementing recent General Counsel and Investor Relations appointments Chief Financial Officer Brian M. Silver leaving Freeline to pursue a new opportunity LONDON, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”), a clinical-stage biotechnology company developing transformative adeno-associated virus (“AAV”) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases, today announced the expansion of its executive leadership team with the appointment of Michael J. Parini to the newly-created role of Preside
HC Wainwright & Co. analyst Patrick Trucchio downgrades Freeline Therapeutics (NASDAQ:FRLN) from Buy to Neutral and lowers the price target from $15 to $6.5.
London-listed Syncona Ltd has agreed to acquire Freeline Therapeutics Holdings plc (NASDAQ:FRLN) in an all-cash transaction for $6.50 per American Depositary Share. This price values Freeline's entire issued share capital at approximately $28.3 million and represents a 51% premium over the closing price before the announcement of Syncona's initial proposal on October 18. The acquisition is expected to close in the first quarter of 2024. If completed, the acquisition will result in the company becoming a wholly owned Syncona portfolio company, and its ADSs will no longer be listed on Nasdaq. In conjunction with the agreement, Syncona is committing to provide Freeline with up to $15 mill
Analysts have provided the following ratings for Freeline Therapeutics (NASDAQ:FRLN) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 2 0 2 0 0 Last 30D 0 0 1 0 0 1M Ago 0 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 2 0 1 0 0 In the last 3 months, 4 analysts have offered 12-month price targets for Freeline Therapeutics. The company has an average price target of $9.75 with a high of $15.00 and a low of $4.00. Below is a summary of how these 4 analysts rated Freeline Therapeutics over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratin
Gainers Shift Technologies, Inc. (NASDAQ:SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection. Treasure Global Inc. (NASDAQ:TGL) climbed 65.1% to $0.5150 after the company announced an AI robot designed to conduct extended-hour live commerce sessions on TikTok. SeaStar Medical Holding Corporation (NASDAQ:ICU) shares climbed 45.3% to $0.6589 after the FDA granted the company’s Selective Cytopheretic Device Breakthrough Device Designation for hepatorenal syndrome. RVL Pharmaceuticals plc (NASDAQ:RVLP) shares gained 31.4% to $0.0670 after falling 12% on Tuesday. RVL Pharmaceuticals said on Oct. 12, the company receive
Upgrades According to National Bank Financial Inc, the prior rating for Brookfield Infrastructure Partners LP (NYSE:BIP) was changed from Sector Perform to Outperform. Brookfield Infr Partners earned $0.38 in the second quarter, compared to $0.13 in the year-ago quarter. At the moment, the stock has a 52-week-high of $38.18 and a 52-week-low of $24.95. Brookfield Infr Partners closed at $25.69 at the end of the last trading period. For FB Financial Corp (NYSE:FBK), Janney Montgomery Scott upgraded the previous rating of Neutral to Buy. In the third quarter, FB Financial showed an EPS of $0.71, compared to $0.68 from the year-ago quarter. At the moment, the stock has a 52-week-high of $44.